TG Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on November 30, 2021. The filing reports a significant regulatory event concerning the Company's oncology pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory update and does not contain financial statement data.
Material Changes and Regulatory Update
On November 30, 2021, the U.S. Food and Drug Administration (FDA) notified TG Therapeutics that it plans to convene a meeting of the Oncologic Drugs Advisory Committee (ODAC). This meeting is in connection with the review of the pending Biologics License Application (BLA) and supplemental New Drug Application (sNDA) for the combination therapy of UKONIQ (umbralisib) and ublituximab (referred to as U2). The proposed indication is for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Management Commentary and Outlook
Management announced a conference call scheduled for November 30, 2021, at 8:30 a.m. to discuss these regulatory updates. The Company has filed a press release as Exhibit 99.1 detailing this development.
Investor Verification Checklist
- Verify the specific date and time of the FDA Oncologic Drugs Advisory Committee (ODAC) meeting.
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the U2 combination therapy.
- Monitor the outcome of the ODAC meeting and its potential impact on the BLA/sNDA approval timeline.
- Confirm the Company's cash runway and liquidity position in the most recent 10-Q or 10-K, as this 8-K does not contain financial data.